The EUA authorized self-collection kit gives consumers a minimally invasive, convenient and quick option to test from the comfort of their home. Results are provided via email within 24 hours of sample receipt.
Available through the Eurofins direct-to-consumer company, empowerDX, the at home test can be ordered online for USD 89.
After completing a questionnaire, consumers will receive the sample collection kit via FedEx.
Eurofins' infectious disease centre for excellence, Viracor, developed the test based on its highly sensitive, FDA EUA-authorized SARS-CoV-2 RT-PCR assay.
The Eurofins US Clinical Diagnostics network has been at the forefront of COVID-19 testing launching its first RT-PCR assay for SARS-CoV-2 on March 13.
Since then, Eurofins has rolled out several highly sensitive and specific assays to thousands of clients nationwide, including hospitals, physicians' offices, nursing homes, government entities, sports organizations and employers.
At-home COVID-19 testing adds additional capability to an already robust menu including pooled testing, antibody testing, wastewater, used-mask, and soon to be launched saliva testing.
Concurrent to ongoing COVID-19 assay innovation, Eurofins has increased capacity throughout its network of labs to ensure sufficient capacity is available for consistency of turnaround time should COVID-19 infections continue to increase in the upcoming weeks.
Since March, Eurofins US Clinical Diagnostics testing capacity has ramped up to over 500,000 samples per week. The turnaround time for results has averaged less than18 hours from receipt in the lab.
The at Home COVID-19 Nasal PCR Test is currently not available in New York, New Jersey, Rhode Island, and Maryland.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT